Muğlu, H.; Sünger, E.; Şeker Can, L.; Hamdard, J.; Açıkgöz, Ö.; Yıldız, Ö.; Ölmez, Ö.F.; Şeker, M.; Bilici, A.
The Prognostic Roles of Systemic Inflammatory Markers Before Abiraterone or Enzalutamide Therapy in Metastatic Castration-Resistant Prostate Cancer. J. Clin. Med. 2025, 14, 6536.
https://doi.org/10.3390/jcm14186536
AMA Style
Muğlu H, Sünger E, Şeker Can L, Hamdard J, Açıkgöz Ö, Yıldız Ö, Ölmez ÖF, Şeker M, Bilici A.
The Prognostic Roles of Systemic Inflammatory Markers Before Abiraterone or Enzalutamide Therapy in Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Medicine. 2025; 14(18):6536.
https://doi.org/10.3390/jcm14186536
Chicago/Turabian Style
Muğlu, Harun, Erdem Sünger, Lamia Şeker Can, Jamshid Hamdard, Özgür Açıkgöz, Özcan Yıldız, Ömer Fatih Ölmez, Mesut Şeker, and Ahmet Bilici.
2025. "The Prognostic Roles of Systemic Inflammatory Markers Before Abiraterone or Enzalutamide Therapy in Metastatic Castration-Resistant Prostate Cancer" Journal of Clinical Medicine 14, no. 18: 6536.
https://doi.org/10.3390/jcm14186536
APA Style
Muğlu, H., Sünger, E., Şeker Can, L., Hamdard, J., Açıkgöz, Ö., Yıldız, Ö., Ölmez, Ö. F., Şeker, M., & Bilici, A.
(2025). The Prognostic Roles of Systemic Inflammatory Markers Before Abiraterone or Enzalutamide Therapy in Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Medicine, 14(18), 6536.
https://doi.org/10.3390/jcm14186536
